Held on 02 May 2017
The Board of Directors of Omkar Speciality Chemicals at its meeting held on 02 May 2017 transacted the following -Adopted the order of Composite Scheme of Arrangement approved by NCLT on 13 April 2017.
To make an investment of Rs 2.23 crore by subscribing to 22,36,445 equity shares of Rs 10 each in Lasa Supergenerics in accordance with the Scheme of Arrangement.
Take on record, upon demerger, transfer of fixed assets and liabilities of the Company to Lasa Supergenerics.
Accepted the resignation of directors with effect from 02 May 2017 - Omkar Herlekar, Subhash Mali, Subhash Ghalke, Dr Suhas Rane and Vikas Gadre.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app